Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Peripheral arterial disease and atrial fibrillation and risk of stroke, heart failure hospitalization and cardiovascular death: a nationwide cohort study
Peripheral arterial disease (PAD) and atrial fibrillation (AF) share several comorbidities and contribute to similar cardiovascular (CV) outcomes. Only few studies have evaluated the correlation between PAD, AF, and their interaction effects on CV outcomes.
Source: International Journal of Cardiology - October 18, 2015 Category: Cardiology Authors: Yu-Sheng Lin, Tao-Hsin Tung, Jui Wang, Yu-Fen Chen, Tien-Hsing Chen, Ming-Sheng Lin, Ching-Chi Chi, Mien-Cheng Chen Source Type: research
Trends in hospitalizations of young patients with atrial fibrillation: A cause for concern?
Atrial fibrillation (AF) is the most common sustained arrhythmia and results in significant morbidity and healthcare cost. Increasing age is a well-recognized risk factor for the development of non valvular AF and AF-related stroke. Recent studies have identified heterogeneity in epidemiological trends of AF, with significant, and growing, prevalence in a younger population [1]. We sought to examine contemporary trends in hospitalization rates, comorbidities, length of stay (LOS), and AF-related mortality in younger vs.
Source: International Journal of Cardiology - October 19, 2015 Category: Cardiology Authors: Abhishek Deshmukh, Naga Venkata Pothineni, Nileshkumar Patel, Apurve O. Badheka, Siva K. Mulpuru, Hakan Paydak, Peter A. Noseworthy Source Type: research
‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand
Anticoagulants such as warfarin and dabigatran can significantly reduce the risk of stroke in individuals with atrial fibrillation that may lead to increased risk of bleeding, especially in older people. Evidence for bleeding risks with anticoagulants within the context of doses, multimorbidity and impaired renal function in real world setting is lacking.
Source: International Journal of Cardiology - November 9, 2015 Category: Cardiology Authors: Prasad S. Nishtala, Danijela Gnjidic, Hamish Jamieson, H. Carl Hanger, Chanaka Kaluarachchi, Sarah N. Hilmer Source Type: research
Altered atrial conduction in postoperative atrial fibrillation
Postoperative atrial fibrillation (POAF) is a common condition and closely associated with length of hospital stay, cost, stroke and death [1]. In this issue of the International Journal of Cardiology, Lazzeroni and associates present a study that analyze the effect of atrial electrical dispersion as assessed by P-wave dispersion (PWD) to predict POAF. They showed that PWD is significantly greater in patients with POAF and showed a linear correlation between PWD and the probability of POAF [2].
Source: International Journal of Cardiology - November 17, 2015 Category: Cardiology Authors: Alptug Tokatli, Omer Yiginer Tags: Correspondence Source Type: research
Usefulness of the SAME-TTR score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea
The objective of this study was to establish if presence of OSA is associated with poor expected benefit from Vitamin K Antagonist (VKA) therapy as assessed using the SAMe-TT2R2 score.
Source: International Journal of Cardiology - November 23, 2015 Category: Cardiology Authors: Filip M. Szymanski, Gregory Y.H. Lip, Krzysztof J. Filipiak, Anna E. Platek, Grzegorz Karpinski Source Type: research
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders
Percutaneous left atrial appendage closure (LAAC) has been recently proposed as a safe and effective strategy to reduce the embolic stroke risk in patients with atrial fibrillation that are not amenable to long lasting oral anticoagulation [1]. After LACC, a temporary double anti-platelets regimen with aspirin and clopidogrel is suggested to prevent closure device thrombosis and enhance its endothelization [2]. Although clopidogrel resistance has been associated with recurrent cardiac events after percutaneous coronary intervention [3], no reports exist concerning the occurrence of LAAC device thrombosis in patients with c...
Source: International Journal of Cardiology - November 24, 2015 Category: Cardiology Authors: Ulrike Ketterer, Giuseppe D´ Ancona, Isabel Siegel, Jasmin Ortak, Hueseyin Ince, Stephan Kische Tags: Correspondence Source Type: research
Association between hyperuricemia and outcomes in patients undergoing percutaneous coronary intervention
Uric acid is the end product of purine catabolism. Lot of previous studies have found that hyperuricemia (HU) as a risk factor for cardiovascular disease such as atrial fibrillation and coronary artery disease [1,2]. Also, HU is a predictor of adverse prognosis in different cardiocerebral disease, such as acute ST segment elevation myocardial infarction, congestive heart failure and acute stroke. However, the predictive value of HU in the prognosis in patients undergoing percutaneous coronary intervention (PCI) is less known.
Source: International Journal of Cardiology - November 28, 2015 Category: Cardiology Authors: Lei Wu, Lan-Ju Yang, Xiao-Yan Meng, Lan-Hua Wang, Yan-Hong Zhou, Tao Liu, Qian-Feng Han, De-Yong Zhang, Heng-Chen Yao Source Type: research
Comparison of watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis
New oral anticoagulants (NOAC) and the Watchman device represent an alternative to warfarin for stroke prophylaxis in atrial fibrillation (AF) patients. However, there are no studies comparing these new treatments. Thus, we performed a network meta-analysis to indirectly compare Watchman and NOACs among AF patients.
Source: International Journal of Cardiology - November 28, 2015 Category: Cardiology Authors: Edward Koifman, Michael J. Lipinski, Ricardo O. Escarcega, Romain Didier, Sarkis Kiramijyan, Rebecca Torguson, Ron Waksman Source Type: research
Prevalence, incidence, risk factors and treatment of atrial fibrillation in Australia: The Australian diabetes, obesity and lifestyle (AusDiab) longitudinal, population cohort study
We sought to describe the prevalence, incidence, risk factors and treatment (according to stroke risk) of atrial fibrillation (AF) in the national, population-based Australian Diabetes, Obesity and Lifestyle (AusDiab) Study cohort.
Source: International Journal of Cardiology - December 14, 2015 Category: Cardiology Authors: Ibrahima Diouf, Dianna J. Magliano, Melinda J. Carrington, Simon Stewart, Jonathan E. Shaw Source Type: research
Impact of Chronic Kidney Disease on Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation
Left atrial appendage occlusion (LAAO) using the Amplatzer cardiac plug (ACP) is preventive treatment of atrial fibrillation related thromboembolism.
Source: International Journal of Cardiology - January 8, 2016 Category: Cardiology Authors: Joelle Kefer, Apostolos Tzikas, Xavier Freixa, Samera Shakir, Sameer Gafoor, Jens Erik Nielsen-Kudsk, Sergio Berti, Gennaro Santoro, Adel Aminian, Ulf Landmesser, Fabian Nietlispach, Reda Ibrahim, Paolo Luciano Danna, Edouard Benit, Werner Budts, Francis Source Type: research
Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings
Large randomized controlled trials have found that in non-valvular atrial fibrillation (AF), non-vitamin K antagonist oral anticoagulants (NOACs) had a favorable risk–benefit profile, with significant reductions in stroke, mortality and intracranial hemorrhage, but possibly increased gastrointestinal bleeding [1]. After the approval of dabigatran, many agencies in different countries received reports of severe dabigatran related bleeding reports through their adverse event reporting system. Concurrently, several case reports of dabigatran induced bleeding were published in medical journals and discussed in the mainstream media.
Source: International Journal of Cardiology - January 6, 2016 Category: Cardiology Authors: Walid Darwiche, Theodora Bejan-Angoulvant, François Dievart, Dominique Babuty, Denis Angoulvant, Laurent Fauchier Tags: Correspondence Source Type: research
Effects of probucol on left atrial remodeling in patients with paroxysmal atrial fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases the risk of stroke and death. An increasing body of evidence indicate the role of inflammation and oxidative stress in the development and perpetuation of AF. Indeed, inflammation and oxidative stress are involved in electrophysiological and structural remodeling of the atria [1–3]. Probucol is a lipid-lowering drug that has potent antioxidant effects. Specifically, it attenuates the production of oxygen free radicals and also acts as a direct superoxide anion scavenger [4].
Source: International Journal of Cardiology - January 5, 2016 Category: Cardiology Authors: Qingmiao Shao, Panagiotis Korantzopoulos, Huaying Fu, Lan Ye, Enzhao Liu, Gang Xu, Guangping Li, Tong Liu Source Type: research
Comparative effectiveness and safety of non-vitamin K Antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease
Non-vitamin K antagonist oral anticoagulants (NOACs) are approved for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). These agents are as effective as warfarin and are associated with less intracranial bleeding and may be preferable for many patients with NVAF [1]. However, the term non-valvular AF remains a source of confusion because clinical trials and guidelines have adopted variable definitions.
Source: International Journal of Cardiology - February 2, 2016 Category: Cardiology Authors: Peter A. Noseworthy, Xiaoxi Yao, Nilay D. Shah, Bernard J. Gersh Source Type: research
Predictive value of circulating fibroblast growth factor-23 on atrial fibrillation: A Meta-analysis
Atrial fibrillation, which can result in stroke and thromboembolism in an approximately 5-fold increased risk, has been a growing burden to health care system with the aging of the population [1,2]. Traditional risk factors for AF have been attributed primarily to hypertension [3], coronary artery disease, heart failure [4,5], valvular heart disease, diabetes mellitus [6,7] and chronic kidney disease [8,9]. However, those risk factors only partly explain the incident and prevalent atrial fibrillation, further identification of novel, modifiable risk factors is eagerly pursued.
Source: International Journal of Cardiology - February 18, 2016 Category: Cardiology Authors: Lei Meng, Yajuan Yang, Zhiwei Zhang, Guangping Li, Tong Liu Source Type: research
Energy metabolic alterations in the progression of atrial fibrillation: Potential role of AMP-activated protein kinase as a critical regulator
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia associated with increased risk of heart failure and stroke [1]. Accumulating studies have revealed that a series of striking alterations in atrial electrical, structural, and autonomic properties is critical to most acquired forms of AF [2–3]. However, the impact of cardiac energy metabolism upon the initiation or persistence of AF is incompletely understood. Metabolomic and proteomic analyses have indicated a close relationship between metabolic dysfunction and AF development [4].
Source: International Journal of Cardiology - March 14, 2016 Category: Cardiology Authors: Jie Qiu, Shenghua Zhou, Qiming Liu Tags: Correspondence Source Type: research
